Trial Profile
A Phase 1/2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Quavonlimab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 07 Feb 2023 Planned End Date changed from 23 Oct 2023 to 24 Apr 2024.
- 07 Feb 2023 Planned primary completion date changed from 23 Oct 2023 to 24 Apr 2024.
- 09 Nov 2022 Planned End Date changed from 8 Aug 2023 to 23 Oct 2023.